Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
State attorneys general are going after generic drug companies. Photo: Rick Bowmer / AP
Forty-six state attorneys general are expanding their lawsuit against generic pharmaceutical companies, alleging the firms colluded to jack up the prices of 15 generic drugs. Two top company executives — Mylan President Rajiv Malik (the No. 2 executive) and Emcure Pharmaceuticals CEO Satish Mehta — also were named as defendants.
Why it matters: States are not only bringing more generic companies into the suit, but also are levying allegations against top drug company executives. This goes to the top brass of the $75 billion generic drug market. And it's now the second time in a week, following the indictment of John Kapoor, that legal officials are going after pharmaceutical executives.